Nanobac Pharmaceuticals Incorporated NNBP

$0.00 0.00 (—)

Valuation

Market cap
0
Revenue TTM
$0
Net income TTM
$0
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
8,000
Avg volume
—
Day's range
$0.00 – $0.00
Shares out
—
Stochastic %K
—
Beta
—
Analysts
—
Price target
—

Price

Company profile

Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical stu...

Show more

Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases. Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
813-865-1125
Address
3000 Bayport Drive, Suite 910, Tampa, United States

Latest news

No headlines yet.

Stocktwits

SorosSonosSatoshi Sep 22, 4:14 PM
$NNBP 1 uss 20 lira 6weeks left
0 replies
70w02ld Oct 8, 11:01 AM 0 replies
SorosSonosSatoshi Jul 17, 10:00 AM
$NNBP what is the price. Here we see only 2 digits after decimals..0.00
3 replies
_BigBullNutz May 26, 10:06 PM
$NNBP #1 👀💎
0 replies